European urology · 2025
Testosterone Therapy in Adult Males with Hypogonadism.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boeri Luca, Masterson Thomas, Antonio Leen, Corona Giovanni, Khera Mohit, Salonia Andrea, Mulhall John P
Аннотация
BACKGROUND AND OBJECTIVE: Testosterone deficiency (TD) is a common condition affecting patients' health and quality of life. Clinical management has changed over the past decades, particularly regarding the indications and outcomes of testosterone therapy (TTh). Our aim was to provide an overview of the available evidence supporting the use of TTh in adult men with TD.
METHODS: A nonsystematic literature review was conducted to identify relevant studies on the diagnosis and treatment of TD. The review encompassed lifestyle and pharmacological approaches, summarizing recent advances and highlighting persisting gaps in clinical practice.
KEY FINDINGS AND LIMITATIONS: Testosterone deficiency in adult men typically presents with mild, nonspecific symptoms often related to aging, including sexual dysfunction, fatigue, mood changes, and reduced muscle and bone mass. Diagnosis requires a thorough clinical assessment and confirmation of low serum total testosterone. TTh is the standard treatment for symptomatic men with TD and low testosterone levels. Evidence indicates that TTh improves sexual function, body composition, metabolic profile, and bone mineral density without increasing the risk of major cardiovascular events or prostate cancer. Current guidelines recommend maintaining testosterone within the midnormal range (450-600 ng/dl) and monitoring hematocrit, prostate-specific antigen, and metabolic parameters. Follow-up should occur at 3 mo and every 6-12 mo thereafter, with individualized adjustments based on clinical response and safety.
CONCLUSIONS AND CLINICAL IMPLICATIONS: TTh is a safe and effective treatment for TD. The selection of the most suitable product should consider patient needs and preferences, as well as the physician's perspective.
METHODS: A nonsystematic literature review was conducted to identify relevant studies on the diagnosis and treatment of TD. The review encompassed lifestyle and pharmacological approaches, summarizing recent advances and highlighting persisting gaps in clinical practice.
KEY FINDINGS AND LIMITATIONS: Testosterone deficiency in adult men typically presents with mild, nonspecific symptoms often related to aging, including sexual dysfunction, fatigue, mood changes, and reduced muscle and bone mass. Diagnosis requires a thorough clinical assessment and confirmation of low serum total testosterone. TTh is the standard treatment for symptomatic men with TD and low testosterone levels. Evidence indicates that TTh improves sexual function, body composition, metabolic profile, and bone mineral density without increasing the risk of major cardiovascular events or prostate cancer. Current guidelines recommend maintaining testosterone within the midnormal range (450-600 ng/dl) and monitoring hematocrit, prostate-specific antigen, and metabolic parameters. Follow-up should occur at 3 mo and every 6-12 mo thereafter, with individualized adjustments based on clinical response and safety.
CONCLUSIONS AND CLINICAL IMPLICATIONS: TTh is a safe and effective treatment for TD. The selection of the most suitable product should consider patient needs and preferences, as well as the physician's perspective.